Down Syndrome and Cell Therapy: A Review
(Sindrom Down dan Terapi Sel: Suatu Ulasan)

NORIZAM SALAMT, RUSZYMAM HAJI IDRUS & NOOR WAHIDAH MOHD NASRI*

ABSTRACT

Cell therapy has been considered as an alternative treatment for many diseases, including Down syndrome (DS). However, this treatment remained debatable due to insufficient clinical data. Therefore, this study aims to identify and evaluate studies on the potential of cell therapy in improving the quality of life of DS patients. Relevant English articles and snowball sampling from Science Direct and PubMed (published until August 2019) on the effects of cell therapy on DS was retrieved. Only original articles on the effect of cell therapy in DS patients or Ts65Dn (trisomic) mice were selected. Two independent reviewers reviewed the articles with selective inclusion criteria using a standard data extraction form. Cell therapy showed no significant findings on the physical appearance, cognitive function, social, and behavior skills of DS patients. Interestingly, implantation of murine neural stem cell (mNSC) or murine neural progenitor cell (mNPC) showed better cell survival and response towards brain injury, decrease tau + granules and increase granules density in the dentate gyrus in the trisomic mice. mNSC/mNPC in mice brain was found to be able to migrate to the sites of the injury following chemokine signals and eventually provide neuroprotection and promote axonal growth. To conclude, mNSC/mNPC implantation could be considered as an alternative treatment for DS or DS with early onset of Alzheimer Disease (AD).

Keywords: Cell therapy; Down syndrome; sicca cell therapy; trisomy 21

INTRODUCTION

Down syndrome (DS), a condition discovered by John Langdon Down, is the most common chromosomal abnormality leading to intellectual disabilities and earlier onset of Alzheimer’s disease compared to the general population (Inoue et al. 2019). There are three causes of DS namely: trisomy 21 (95%), translocation (4%), and mosaicism (1%) (National Down Syndrome Society 2019).
Triplication of chromosome 21, specifically at band 21q22, is associated with characteristic facial and physical appearances, congenital heart defects, reduced immunity, and mild-to-moderate global cognitive impairment (Lott & Dierssen 2010; Roizen & Patterson 2003; Zigman et al. 2008). Thus far, there is no single standard treatment for DS. However, advances in medical treatments and interventions, as well as changes in social attitudes, give better life expectancy to DS patients (Glasson et al. 2016). The life expectancy of DS has been shown to greatly increased from 25 years in 1983 to 60 years until now (Caraci et al. 2017). There is also the availability of other alternative therapies, such as drug, physical, antioxidant, gene, and cell therapies that offer positive improvements by reducing the symptoms of DS (National Institute of Neurological Disorder & Research 2015).

Cell therapy is considered as an alternative treatment for major chronic diseases (Fisher et al. 2016; Lindvall & Kokaia 2006; Shen et al. 2016). In 2016, there are 417 websites worldwide advertising stem cell treatments directly to the patients whereby 187 of the websites were linked to clinics in the US and 35 were linked to organizations in India (Coghlan 2017). In Malaysia, Xenogenic cells and anti-aging/skin care interventions are offered by most of the clinics (Berger et al. 2016). Gopalan et al. (2017) reported on a controversial stem cell therapy treatment extracted from rabbit for DS patients. However, only stem cell bone marrow and peripheral blood stem cell transplantation for the treatment of haematological disorders such as leukaemia and thalassemia were approved by the Ministry of Health Malaysia (MOHM) (Ministry of Health 2015).

Subcutaneous administration of freeze-dried or lyophilized fetal cells (sicca cell) has been suggested as a treatment for DS (Roizen 2005) as early as the 1950s (Van Dyke 1990). The cells were derived from various organs of fetal cattle, sheep, and rabbit (Roizen 2005; Van Dyke 1990). A claim has been made that sicca cell therapy is able to enhance dysmorphic features of DS and improves intelligence quotient (IQ), motor skills, social behavior, height, language, and memory (Van Dyke et al. 1990).

The mechanism behind the action could be through the migration of the cells into the targeted organs where the injected cells help to revitalize the target organ (Pueschel & Pueschel 1992). Sicca cell therapy may also increase the IQ of DS children by normalizing the brain volume index with a condition that the therapy started in the early infancy (Pueschel & Pueschel 1992). The disadvantage of sicca cell therapy is it may induce allergic or hypersensitivity reactions by transmitting the virus between injections and potentiate seizures (Van Dyke et al. 1990). A previous study on a two-month-old DS newborn injected with human embryonic stem cells showed a better understanding, remarkable improvement in limb muscle tone, and increase ability to recognize nearby placed objects after multiple injections (Shroff 2016). These improvements were made possible by the ability of the stem cells to repair and regenerate (Shroff 2016).

Cell therapy treatment remains inconclusive without supporting evidence from randomized, controlled or independent clinical trials. One such example was a report on the alleged use of stem cells that were given through intravenous, intramuscular, and subcutaneous injection to treat 14 DS patients in a clinic in New Delhi, India (Coghlan 2017). The lack of data on the comparison to a similar individual with DS and the route of administration made the findings in this report questionable (Coghlan 2017). Standard treatments and therapies for DS are only recommended after a thorough large, randomized, double-blind research studies that evaluate the safety, efficacy, benefits, risks, and side effects of any treatment given (US National Down Syndrome Society 2019). Therefore, this study aims to identify and evaluate scientifically approved studies on the potential of cell therapy in improving the life quality of DS patients. This review will be able to help those who seek realistic hopes from this kind of treatment for DS patients.

MATERIALS AND METHODS

LITERATURE REVIEW

Previous literature review to identify relevant studies focusing on the effects of cell therapy on DS was conducted. A comprehensive search was performed until August 2019 in Science Direct and PubMed databases. The search strategy involved a combination of two keywords namely: ‘Down syndrome’ AND ‘cell therapy’.

SELECTION OF RESEARCH ARTICLES

This review only included full articles that were published in the English language that reported the effects of cell therapy on DS in human or animal model. Any other forms of articles including review articles, conference abstracts, supplementary issues, poster presentations, book chapters, short communications, letter to the editor, case reports, news, encyclopaedia, and consensus/statement/guideline were excluded from this review.
INCLUSION AND EXCLUSION CRITERIA
Studies in this review met the following criteria including: articles that showed direct effects of cell therapy on DS in human or animal model, articles that reported an administration of any type of cell in human or animal model with DS, and the participants in human studies were children or adults diagnosed with DS regardless of age. Studies that use a human model with DS but diagnosed with any serious diseases such as cardiovascular disease and leukaemia were excluded.

DATA EXTRACTION AND MANAGEMENT
The selection of potential articles in this review was conducted in three phases namely: exclusion of any articles with title and keywords that did not meet the inclusion criteria, exclusion of abstract that did not fulfil the inclusion criteria, and selection for the final articles was made after a thorough reading by two independent reviewers. Any conflict in selecting the articles was resolved by analytical discussions between the two independent reviewers in order to reach a mutual agreement. Data extraction table was designed to collect standardized data.

The following information was extracted from the studies such as: author, title and year of the publication; subject and age; methods of the cell therapy intervention; and effect of cell therapy on DS.

SEARCH RESULTS
The literature search in Science Direct and PubMed databases discovered 107,596 potentially relevant articles. Around 106,918 items were excluded during the first phase as the articles were not associated with DS based on the titles, keywords, and abstracts. Another 308 original study articles were further excluded. A further 66 out of 370 remaining articles were excluded due to the use of non-cell-based therapy such as drug and hormone on the human model presented with chronic diseases. A snowball or hand selected search was carried out and another 3 potential articles were retrieved. A total of 7 articles were included in this review after thorough reading by the reviewers. Any differences of opinion between the reviewers were resolved through discussion. The flow diagram of the different phases of the systematic review is shown in Figure 1.

FIGURE 1. Selection article process
STUDY CHARACTERISTICS

Table 1 shows the characteristics of the final articles selected that fulfil the inclusion criteria. The recent publication that was used in this review is August 2019. The 7 published articles used in this review used different cell types and route of administration using human or animal models with DS. There were only 4 studies conducted in human reported the age group of the participants (Bardon 1964; Black et al. 1966; Foreman & Ward 1987; Van Dyke et al. 1990). Furthermore, there were 3 animal studies on Ts65Dn mice with the characteristics of DS were selected (Kern et al. 2011; Rachubinski et al. 2012a, 2012b). In a retrospective study conducted by Van Dyke et al. (1990) on 190 DS participants, only 21 participants received cell therapy some time in their life. In another study, Foreman and Ward (1987) compared 23 DS children with age and sex matched control children. The participants received cell therapy through injection, however, the specific cell type and route of administration were not highlighted. Sicca cell was used in Bardon (1964) and Black et al. (1966) intervention studies, however, only Black et al. (1966) study reported the route of administration of the injected cells through intramuscular. The animal model studies on Ts65Dn mice used murine Neural Progenitor Cell (mNPC) (Rachubinski et al. 2012a, 2012b) and murine Neural Stem Cell (mNSC) (Kern et al. 2011). All treated mice were injected with particular cells into the specific region of the hippocampus (Kern et al. 2011; Rachubinski et al. 2012a, 2012b). There were no significant improvements between DS children and normal children reported in all of the human studies. In contrast, all animal models showed promising effects on brain development or neurodegeneration prevention after cell therapy treatment.

<table>
<thead>
<tr>
<th>Author (year)</th>
<th>Subject (n); age</th>
<th>Method</th>
<th>Result</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bardon (1964)</td>
<td>DS children (10); not mentioned</td>
<td>Treatment group: Received 5 mL of sicca cell injection</td>
<td>No significant effect even after 2 years of observation</td>
<td>Sicca cell treatment failed to demonstrate any effect on DS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Control group: Did not received any treatment</td>
<td>Assessment: 1. Intelligence (Griffith development scale) 2. Motor behaviour</td>
<td></td>
</tr>
<tr>
<td>Black et al.</td>
<td>Mentally retarded children (59); not mentioned</td>
<td>35 out of 59 subjects were children with DS</td>
<td>1. IQ score: No significant differences between treatment and control groups 2. Academic rating, behaviour and sense training: -No differences in the distribution of subjects in treatment and control groups in their class standings -Teacher was not able to distinguish the subject in the treatment or control group 3. General health, coordination, behavior and awareness: - No significant differences between treatment and control groups - Parents were not able to distinguish their children was in the treatment or control group</td>
<td>Sicca cell treatment failed to demonstrate any effect on DS and other mentally retarded children</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Treatment group: Received sicca cell injections (intramuscular) three times for every six months</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Control group: Received multiple injections either in lung, liver, or muscle for preparation</td>
<td>Assessment: 1. IQ score 2. Academic rating, behavior and sense training 3. General health, coordination, behaviour, and awareness</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Group</td>
<td>Treatment</td>
<td>Assessment</td>
<td>Results</td>
</tr>
<tr>
<td>-------</td>
<td>-------</td>
<td>-----------</td>
<td>------------</td>
<td>---------</td>
</tr>
<tr>
<td>Foreman &amp; Ward (1987)</td>
<td>DS children (n=46); Boys - 62.6 months (treated); 59.1 months (control); Girls - 57.4 months (both groups)</td>
<td>Treatment group: Received cell therapy injection for 3-7 days</td>
<td>1. General development: Not significant between gender - significant improvement in performance scale in children &gt;40 months (p&lt;0.05)</td>
<td>Treatment with cell therapy failed to show significant effects for children with Down syndrome</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Control group with DS: Answer questionnaires</td>
<td>2. Physical characteristics: Not significant</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Assessment: 1. General development, motor functioning, language development, and social development 2. Height, weight, and head circumference 3. Facial appearance 4. Hair quality 5. Skin quality</td>
<td>3. Facial appearance: Not significant 4. Hair quality: force in grams was significant (p&lt;0.05) 5. Skin quality: not significant</td>
<td></td>
</tr>
<tr>
<td>Van Dyke et al. (1990)</td>
<td>DS person (n=190); 2 months – 19.2 years</td>
<td>21 out of 190 DS children received one or more injections of cell therapy were matched with persons with DS who had not received cell therapy (retrospective study)</td>
<td>1. Growth: Not significant 2. Social adaptive: Not significant 3. Motor Development: Not significant 4. Cognitive Development: Not significant</td>
<td>This retrospective study showed no statistically significant differences for any 18 social development or growth variables measured</td>
</tr>
<tr>
<td>Rachubinski et al. (2012a)</td>
<td>Ts65Dn mouse pups</td>
<td>Type of animal: Ts65Dn mouse Cell Line: C17.2 murine Neural Progenitor Cell Dosage: 100,000 undifferentiated C17.2-GFP mNPC (1 µL) (treatment group) or with 1 µL sterile 0.09% saline (control group) Location of implant: Injections in the dorsal hippocampus (+2 mm AP, 61 mm LM, 22.5 mm DV from lambda)</td>
<td>1. Weights and developmental milestones: - no significant effect on the weight gain 2. Survival of the mNPC in the host brain: - trisomic brains have better cell survival in the hippocampus than disomic brains (p&lt;0.0001) 3. Quantification of granule cell density in DG: - implantation of mNPC significantly increases the density of granule cells by 33% compared to the non-treated group (p&lt;0.05) 4. Neuroimmune response to implantation: - no long-term immunoreactivity was detected 16 weeks after implantation</td>
<td>The implantation of mNPC resulted in a significant increase in the density of dentate granule cells but did not elicit cognitive changes in the trisomic mice either neonatally or adulthood</td>
</tr>
</tbody>
</table>
Assessment:
1. Baseline weights
2. Survival of the mNPC in the host brain
3. Quantification of granule cells of the dentate gyrus
4. Quantification of the number of neurons per mm² area
5. Behavior Testing (Neonatal) - righting response, cliff avoidance behavior, negative geotaxis response, and eye and ear opening

- Righting response: not significant
- Cliff avoidance: not significant
- Negative geotaxis: treatment with mNPC delayed the development of the disomic group to a level comparable to trisomic group (p<0.05). No significant differences between the implanted and untreated trisomic group
- Eye and ear opening: not significant
  Treatment with mNPC produced a delay of 11.0 hours in ear opening in disomic mice compared to untreated trisomic mice (p<0.05)

- Plus maze: Treatment with mNPC significantly improve the performance in trisomic mice (p<0.05)
- Morris water maze: not significant
- CTA: not significant
- NOR: not significant

Rachubinski et al. (2012b) Ts65Dn aged mouse (11-12mo) Type of animal: retired female breeders from the Ts65Dn colony, which had been implanted on PND2

Cell Line: C17.2 murine Neural Progenitor Cell

Dosage: 100,000 undifferentiated C17.2-GFP mNPC (1 µL) (treatment group) or with 1 µL sterile 0.09% saline (control group)

Location of implant: Injections in the dorsal hippocampus (+2 mm AP, 61 mm LM, 22.5 mm DV from lambda).

Assessment:
1. Behavioral testing:
   - Treated trisomic mice have improved performance in the CTA but not NOR
   - Treatment with NPC or saline impaired the cognition of the disomic mice

2. Hippocampal neuroanatomy:
   - More NPC was found in the trisomic brains than in the disomic brains (p<0.05) but no difference between the saline implanted and the NPC implanted brains
   - Unimplanted brains had significantly more neurons than either saline or NPC implanted brains (p<0.05)
   - Implanted brains were significantly reduced in the number of granule cells compared to unimplanted brains (p<0.05) but no difference between the saline implanted and the NPC implanted brains
   - Saline-treated brains have higher tau+ granule counts than all groups, while NPC implanted brains more closely resembled the untreated brains

Implantation during neonatal increase the survival of the NPC in the brain of the trisomic mice. However, it showed modest cognitive improvements and reduced tau+ accumulations and these might be due to more potent effects of the implantation procedure.
| Kern et al. (2011) | Ts65Dn aged mouse (12mo) | Type of animal: Ts65Dn mouse | -Clusters of granulated protein accumulation was found in both aged (13 months) disomic and trisomic Ts65Dn mice
-Extrasomatic granules were located primarily in the hippocampus and olfactory bulb
-Granules in the aged trisomic and disomic Ts65Dn mice appear to be similar in size, appearance, and location as granules described in aged C57BL/6 mice and murine AD models.
-No Aβ plaque deposition in the brains of the aged Ts65Dn mice
-A strong tau and less strong reelin detected in the granules found in the disomic and trisomic Ts65Dn brain
-Extracellular clusters in the disomic and trisomic brains were positive for reelin
-Trisomic mice had three times the number of tau/reelin-positive granules as disomic mice and the majority of hippocampal tau/reelin-positive clustered granules were located in Rad/LM of CA1 in the hippocampus |
| Cell Line: C17.2 murine Neural Stem Cell (mNSC) | Dosage: 500,000 viable disomic mNSCs (1 µL) (treatment group) or with 4 µL sterile saline (control group) | NSC implantation reduces tau/reelin accumulation in the aging DS and AD. These changes can be used as an index for neuropathological assessment in aging DS and AD |
| Location of implant: Injections in the hippocampus (-2.0 mm AP, -2.0 mm ML, 1.5 mm DV relative to bregma) | Assessment: 1. Quantification of protein accumulations in the hippocampus: the three layers of CA1 and CA3 (Rad/LM, the pyramidal cell layer, and stratum oriens), and the dentate gyrus (DG) |

**RESULTS AND DISCUSSION**

**HUMAN STUDY**

In this review, 4 studies were conducted on human with DS between the year of 1964 and 1990. All studies showed irrelevant effectiveness of cell therapy in improving the quality of life of DS. Only 3 studies showed the use of sicca cell as the injected cell type (Bardon et al. 1964; Black et al. 1966; Van Dyke et al. 1990) whereas Foreman and Ward (1987) study has no report on the type of cell used. All study reported injection as the main route of administration, however, only 1 study specifically mentioned the intramuscular as the specific site of injection (Black et al. 1966). The frequency of injection was also different in each study with: one or more injection (Van Dyke et al. 1990), between 3-7 injections with 6-12 months apart (Foreman & Ward 1987), and 3 series of administration approximately 6 months apart (Black et al. 1966). Only 1 study with no reports on the numbers of injections given to the subject (Bardon et al. 1964). The parameters measured include physical appearance, cognitive, behavior, and skills development (Table 2). There were no significant effects of cell therapy treatments observed on the participants with DS, which could be due to several reasons including: no specific type of cell, no specific dose or volume of the injected cell, and non-suitable route of cell administration. The main flaw in all of the human studies was no discussion on the characteristics of the injected cells used in the studies (Bardon et al. 1964; Black et al. 1966; Foreman & Ward 1987; Van Dyke et al. 1990).
TABLE 2. Parameters measured in the DS patients after cell injection

<table>
<thead>
<tr>
<th>Type of parameter</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical appearance</td>
<td>Height, weight, head circumference, middle arm circumference, arm muscle circumference, subscapular skinfold, triceps skinfold, facial appearance, hair quality, skin quality</td>
</tr>
<tr>
<td>Cognitive</td>
<td>IQ score, academic rating, mental development</td>
</tr>
<tr>
<td>Behavior</td>
<td>Social, adaptive behavior composite</td>
</tr>
<tr>
<td>Skills</td>
<td>Motor, language, daily living</td>
</tr>
</tbody>
</table>

ANIMAL STUDY

The 3 studies on animal models used in this review evaluate the effectiveness of cell therapy on Ts65Dn mice. Ts65Dn was the most common strain of mice used in the DS model with 426 entries in PubMed until August 2019 (PubMed 2019). This mouse model carries T(17;16) translocation that resulted in two-thirds of the human chromosome 21 homologue in its chromosome 16 segment (Reinholdt et al. 2011). Chromosome 16 of the Ts65Dn mice is orthologous to 67% of human chromosome 21 that mimics the physical and cognitive phenotypes of a DS human being. Thus, Ts65Dn becomes the most suitable model for drug development with the aim of improving behavioral and cognitive function of DS (Smith et al. 2014). Several studies reported the use of older Ts65Dn mice (11-12 months old (Kern et al. 2011; Rachubinski et al. 2012b) or mice pups (Rachubinski et al. 2012a) as their subjects. Rachubinski et al. (2012b) study reported the effect of implanted mNPC on retired female breeders from the Ts65Dn colony while mNSC was used in Kern et al. (2011) study. Rachubinski et al. (2012a) also showed a similar mNPC resident population of microglia and astrocytes and absence of glial scarring between the implanted and unimplanted mice indicating no long-term immunoreactivity up to 16 weeks post implantation. In addition, Patil (2018) reported the use of neural stem and progenitor cells to compensate and replace the defective cells in chronic diseases. Similar findings showed NSC/NPC transplantation in the brain was successfully migrated to the damage sites and significantly improves injury-induced spatial learning deficits. The reduction of astrogial activation and microglial/macrophage was observed while enhancing the mobilization of endogenous oligodendrocyte precursor cells (Koutsoudaki et al. 2016). Therefore, due to these characteristics, NSC was postulated as the potential treatment for DS or DS with the early onset of AD. DS is usually presented with increase amyloid-β (Aβ) deposition, which is believed to be related to the triplication and lifelong overproduction of amyloid precursor protein (APP) gene (a gene located at chromosome 21) (Wiseman et al. 2015; Zis & Strydom 2018).

Implantation of mNPC in Ts65Dn mice showed trisomic mice have a better proportion of cell survival in the hippocampus compared to the disomic mice after four months post-implantation (Rachubinski et al. 2012a). Implanted cells were often subjected to collateral damage and death due to the wound healing process induced by the transplant procedure. Therefore, it was possible that these detrimental effects were lessened in the trisomic brain to allow higher chances of survival (Bjugstad et al. 2008; Bosch et al. 2004; Ebert et al. 2010; Jing et al. 2009; Kazma et al. 2010). In addition, mNPC were abundant at the site of injection indicating that hippocampus of trisomic mice was compromised but was not enough to affect the cognition ability (Rachubinski et al. 2012a). In aging trisomic mice, majority of the mNPC migrated away from the hippocampus towards the subventricular zone (SVZ) (Rachubinski et al. 2012b).

The migration of mNPC towards SVZ appears to be age-related as cell identification in both studies were conducted at a different period, which was at 4- and 12-months post-implantation and there was no difference in the migration pattern for trisomic and disomic mice (Rachubinski et al. 2012a, 2012b). During aging process, mNPC in SVZ and the subgranular zone (SGV) shift to a quiescent state. However, the SGV of mNPC can be reactivated through exercise and nutrient enrichment whereas the mNPC of the SVZ remain quiescent (Bouab et al. 2011; Chakrabarti et al. 2011; Lugert et al. 2010;
Yang et al. (2011). The reactivation of mNPC in SGV may signify neurogenesis in which the new granule cells grow inside the dendrites into a molecular layer hence extending the axons into the CA3 region. This axonal outgrowth is facilitated by the tau protein (Fuster-Matanzo et al. 2012). Tau is a protein that modulates the stability of axonal microtubules and is also associated with intracellular neurofilibrillary tangles (NFT). Reelin is an extracellular glycoprotein important for laminar structuring in the brain, for synaptic plasticity, and for modulating tau phosphorylation (Deutsch et al. 2006; Frotscher 1997; Niu et al. 2008). Disrupted reelin signaling was associated with increased tau phosphorylation, which will progressively disrupt the neuronal cytoskeleton and displaced by the appearance of NFT (Bloom et al. 2014). The presence of Aβ plaques and NFT marked the onset of AD in DS at the age of 40 years old (Leverenz & Raskind 1998). It is estimated that at the age of 60 years old, two-thirds of DS experienced clinical dementia (Mccarron et al. 2014). Tau/reelin-positive granules most likely represent a degenerative event whereby the core contains cellular debris from the cell loss surrounded by the evidence of ongoing neurodegeneration. Both studies by Kern et al. (2011) and Rachubinski et al. (2012b) reported that more tau-positive granules were found in aging trisomic mice compared to the aging disomic mice. After a month of NSC implantation, aging trisomic and disomic mice showed a reduced number of tau/reelin-positive granules. This suggests that NSC might regulate tau phosphorylation and facilitate healthy neuron by producing growth factors (Elliott et al. 2006; Kamie et al. 2007; Niles et al. 2004). Therefore, the decrease in growth factor synthesis was a prominent characteristic in DS, AD, and normal aging (Pallas et al. 2008; Tomobe & Nomura 2009).

DS was also associated with hypocellularity in the dentate gyrus (DG) due to reduced cell proliferation and increased apoptosis (Lopez-Hidalgo et al. 2016; Lorenzi & Reeves 2006). Although there were no differences in the granule cell density between trisomic and disomic mice, the density of the granule cells was significantly increased after implantation with NPC compared to the untreated mice (Rachubinski et al. 2012a). This condition resulted from the significant decrease of the granule cells diameter in the NPC implanted brain as indicated by reduced space between the cells and a column-like assembly structure (Rachubinski et al. 2012a). The implantation of NPC was speculated to have an indirect effect by facilitating the environment that promotes endogenous DG neurogenesis (Insausti et al. 1998), thus, benefitting the aged Ts65Dn mice that have fewer neurons in DG (Hattiangady et al. 2007). Surprisingly, significant differences in the hypocellularity in DG was not observed in 12 months post-implanted NPC brains between trisomic and disomic mice (Rachubinski et al. 2012b) although some studies showed fewer neurons in Ts65Dn mice (Llorens-Martin et al. 2010; Lorenzi & Reeves 2006; Shichiri et al. 2011). This may be due to the enrichment during the early life whereby NPC was implanted two days after birth (PND2) and mice were handled daily in order to measure their developmental milestone achievement (Rachubinski et al. 2012a). Postnatal stimulation also demonstrated neurogenesis in DG in wild-type and Ts65Dn mice (Chakrabarti et al. 2011; Lemaire et al. 2006).

Ts65Dn mice were implanted with NPC two days after birth (PND2) and the cognitive function was assessed by Rachubinski et al. (2012a). The study showed that achievement of motor skills, specifically righting response, cliff avoidance and negative geotaxis was seen between 5-10 days after birth, whereas eye and ear opening emerged between PND11-13 (Rachubinski et al. 2012a). No significant body weight changes among disomic and trisomic mice pups were observed either in treated or control groups (Rachubinski et al. 2012a). No significant effects on all cognitive function tested in neonatal mice that were treated with mNPC (Rachubinski et al. 2012a) due to low numbers of surviving mNPC in the brain. In contrast, implantation of mNPC only improved conditioned taste avoidance (CTA) in the trisomic aging mice (Rachubinski et al. 2012b). Surprisingly, saline implantation in the disomic mice resulted in a detrimental effect on the mice’s cognitive performance in both CTA and Novel Object Recognition task (NOR). Moreover, this study also showed a different wound healing/neuroimmune response towards brain injury in disomic and trisomic mice after implantation procedure (Rachubinski et al. 2012b). The overexpression of superoxide dismutase 1 (SOD1), a tripped gene in both human and Ts65Dn mice, may provide additional protection for trisomic mice from reactive oxygen species (ROS) generated during injury (Dimayuga et al. 2007; Sebastiá et al. 2004). Increase release of growth factors during injury allows more repair to the trisomic brain compared to the normal condition (Bianchi et al. 2010; Bimonte-Nelson et al. 2003). Injury induced excitotoxicity from free glutamate might be unfavorable due to reduced glutamate-receptor activity in the trisomic mice (Belichenko et al. 2009; Costa & Grybko 2005; Kleschevnikov et al. 2004).
CONCLUSION

In this review, cell therapy was unable to show its effectiveness in improving physical appearance, cognitive, behavior, and skills development in DS patients. These might be due to the incomplete information on the type of cell implanted, the right dosage, and route of administration reported in these studies. In contrast, animal models exhibited a promising outcome with an administration of NSC/NPC into the hippocampus of Ts65Dn mice was able to improve cognitive function and symptoms of AD in the trisomic mice. Furthermore, the application of NSC/NPC in DS patient could be limited by: the invasive therapy as the cells need to be injected directly into the brain for maximum efficacy, the effects were limited to the implantation site and close areas, the effects may be short-lived, and the potential risk of injury due to implantation process. In addition, public awareness is necessary on the possible risk of injecting cell into the body as any unproven treatment without solid and sound evidence might be harmful and a waste of money. Cell therapy is considered as one of the potential therapies in DS, however, more studies are needed to provide sufficient data on the safety and efficacy on its effectiveness on patients with DS.

REFERENCES


